10 results about "Retinal function" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing symmetric or asymmetric optic with aspheric surface which redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The intraocular lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the intraocular lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the intraocular lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

A system for testing different regions of the retina of a subject for retinal function, said system comprising: a monitor configured to display a visual electrophysiology stimulus to the subject, wherein the visual electrophysiology stimulus comprises a four ring visual electrophysiology stimulus; at least one active electrode; at least one reference electrode; and a computer configured to receive electrical signals from said at least one active electrode and said at least one reference electrode, and process the electrical signals.

This invention belongs to the field of biopharmaceuticals and relates to a gene therapy drug for hereditary retinal dystrophy related to RLBP1 gene mutations and its application. Specifically, it involves constructing a recombinant AAV-RLBP1 gene therapy drug, which is then injected intravitreally to infect retinal pigment epithelial cells and Müller cells, causing them to express complete and active RLBP1 protein. This invention utilizes a modified AAV vector to package codon-optimized human RLBP1-cDNA, enabling the expression of complete and active RLBP1 protein, which participates in the visual circulation pathway, rescuing retinal dysfunction caused by pathogenic mutations in the RLBP1 gene, improving visual function in patients, or delaying disease progression.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

The application relates to a retinal cell type-based visual function related parameter acquisition system and belongs to the technical field of medical auxiliary systems. The application aims to accurately acquire a retinal cell type-based visual function related parameter acquisition system of L cone, M cone, S cone, ipRGCs and other different retinal cell type function related physiological parameters. The system of the application comprises a stimulation presentation module, a brightness calibration module, a biological signal acquisition module, a multi-dimensional parameter extraction and cell type specific parameter decoupling module, a parameter analysis and standardized output module, a user interaction module and a data storage module. The application can provide a portable, objective, non-invasive and cell type specific retinal function related parameter acquisition technology, provide comprehensive and reliable technical support for visual function evaluation, is suitable for large-scale parameter acquisition and home monitoring, and solves many limitations of the prior art.

Methods and compositions for treating uveitis are provided. The methods include administering to a subject a single-domain antibody (sdAb) comprising the amino acid sequence set forth in SEQ ID NO:1. In certain embodiments, the sdAb is administered systemically at a therapeutically effective dose and inhibits STAT3 activation in CD4+ T-cells, thereby reducing Th17-mediated inflammation. The methods may be used to treat autoimmune uveitis and may improve retinal function as measured by electroretinogram (ERG) amplitude. Also provided are pharmaceutical compositions comprising the sdAb and a pharmaceutically acceptable carrier. Further methods of modulating immune responses associated with uveitis are disclosed, including reducing cytokine production and T-cell-mediated inflammation.

The invention relates to a visual cortical nerve regulation and control method based on theta explosive type transcranial magnetic stimulation, the method adopts a magnetic resonance guided MNI coordinate system to position an occipital pole stimulation area, the visual cortical layer is a primary visual cortical layer, the theta explosive type refers to a theta explosive type stimulation mode, and the theta explosive type refers to a theta explosive type transcranial magnetic stimulation mode. The TMS breaks through the limitation that a traditional therapy focuses on retina local repair, cortex-retina function compensation is achieved by regulating visual cortex nerve plasticity, clinical data shows that BCVA of an MMD patient can be averagely improved by 0.22 log MAR, the macular sensitivity is remarkably improved, the treatment effect on extreme myopia patients with the axial length larger than or equal to 32 mm is better, and the application prospect is wide. The treatment blank that the existing invasive therapy is taboo due to the fragile eyeball structure is filled. The non-invasive operation avoids the risk of operative complications, no adverse reaction report exists in the treatment process, the tolerance of a patient is good, the curative effect is kept stable in follow-up visit of four weeks, and repeated invasive operation is not needed.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing a piggyback lens which in combination with the cornea and an existing lens in the patient's eye redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The piggyback lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the piggyback lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the piggyback lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

The application discloses a flexible near-infrared artificial retina device and a preparation method thereof. The flexible near-infrared artificial retina device comprises a flexible substrate, a bottom electrode formed on the flexible substrate, a functional layer comprising an organic ferroelectric polymer film, a rare earth up-conversion nanomaterial and an organic ferroelectric polymer film laminated structure formed on the bottom electrode, and a top transparent electrode formed on the functional layer. The device is excited by near-infrared light, the near-infrared light signal is converted into a reproducible visible light signal by using the anti-Stokes luminescence capability of the rare earth up-conversion nanomaterial, the collection and signal reproduction functions of the near-infrared waveband light information are completed, the processing and memory of the near-infrared information are realized by using the continuously adjustable non-volatile resistance state, and finally the simulation of the artificial retina function is realized.